Trial Profile
A double-blind, randomized investigator-initiated study to determine the safety and the effect of Diamyd on the progression to type 1 diabetes in children with multiple islet cell autoantibodies
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Oct 2023
Price :
$35
*
At a glance
- Drugs GAD65 vaccine (Diamyd) (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- Acronyms DiAPREV-IT; DiAPREV-IT 1
- 26 Oct 2023 According to a Diamyd Medical AB media release, results were presented in 2017 in Pediatric Diabetes.
- 30 May 2022 According to a Diamyd Medical AB media release, data from this trial have been published in the scientific journal Journal of Immunology Research.
- 01 Sep 2020 Data from HLA analysis of DiAPREV-IT 1 and 2 trials presented in a Diamyd Medical AB Media Release.